Cure Rate Soars For Some AML Patients Receiving High-Dose Drug

COLUMBUS, Ohio -- A drug given at levels substantially higher than the standard dose can cure nearly five times as many patients who have a certain type of acute myeloid leukemia (AML), new research shows.

The study revealed that 78 percent of patients with “core binding factor” AML who received the drug cytarabine at high dose were in complete remission five years after treatment (and therefore potentially cured) compared to only 16 percent who received the standard dose.

“It is truly remarkable to achieve a cure rate of over 75 percent in a subgroup of adult leukemia patients; this rate approaches that for some types of childhood leukemia,” said Clara Bloomfield, director of Ohio State University's Comprehensive Cancer Center and William G. Pace III Professor of Cancer Research.

“Because high-dose cytarabine is quite toxic, especially for older people, we want to use it only with those patients who will benefit. These results tell us which patients we can cure, and which ones should receive other therapy.”

The finding is considered particularly strong because the study had followed patients for more than seven years after treatment; most such studies rely on models to project estimates of five-year remission rates.

The study, which was led by Bloomfield, appeared in the September issue of the journal Cancer Research. It involved 285 newly diagnosed AML patients aged 16 and older who were in remission. During the second phase of their treatment, a phase known as “intensification therapy,” the patients were randomly assigned to receive cytarabine at either standard dose (100 milligrams per square meter

Contact: Clara Bloomfield
Ohio State University

Page: 1 2 3

Related medicine news :

1. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
2. Patients with cancer have highly increased risk for blood clots
3. Patients with previous heart attacks may not benefit from pacemaker implant
4. Patients with cancer detected on screening mammography undergo less toxic treatment
5. Patients with moderate or severe hand dermatitis responsive to drug therapy
6. Patients with abdominal trauma at risk for intra-abdominal infections following surgery
7. Patients who are intubated prior to hospital arrival fare worse find Pitt researchers
8. Patients undergoing weight loss surgery have high rates of H pylori bacteria
9. Patients with chronic sinus do not necessarily develop antibiotic resistance
10. Plastic surgeons honor Patients of Courage overcoming difficult obstacles, inspiring others
11. Patients with severe depression improve using guidelines developed by UT Southwestern researchers

Post Your Comments:
TAG: Cure Rate Soars For Some AML Patients Receiving High Dose Drug

(Date:10/9/2015)... ... October 09, 2015 , ... MMJ ... Innovations with Ed Begley Jr., airing 1st QT 2016 via the Discovery Channel. ... on MMJ Phytotech Limited (MMJ) – a global leader in the field of ...
(Date:10/9/2015)... ... 2015 , ... Ryan Fox, the founder and CEO of ... says the latest figures on the state’s sales of legalized marijuana acknowledge that ... , Last month, according to the website AllGov.com , Colorado's Department ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... Most people ... processed with more vegetables and less meat. While noted T’ai Chi Master and integrative ... “Yin and Yang” relationship between the two cuisines and that they potentially complement one ...
(Date:10/9/2015)... Florida (PRWEB) , ... October 09, 2015 , ... A variety of race options will ... Treatment of Co-occurring Disorders on Sunday, October 18, at Al Lopez Park, 4810 North Himes ... and will include the choice of a 5K run or walk and a one-mile walk, ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... of Kimberly Post, CPA , as Chief Financial Officer. Kimberly will ... compliance and assist with any strategic acquisitions. Kimberly’s experience guiding healthcare services ...
Breaking Medicine News(10 mins):
(Date:10/8/2015)... Calif. , Oct. 8, 2015  Ardelyx, ... company focused on gastrointestinal and cardio-renal diseases, today ... product candidate, tenapanor, will be presented at the ... presented findings will include measures of sustained response ... double blind, placebo-controlled, randomized Phase 2 trial. The ...
(Date:10/8/2015)... 8, 2015  Trovagene, Inc., (NASDAQ:   TROV) ... the presentation of results from a field experience ... Monitoring SM (PCM) platform to accurately identify ... to determine appropriate therapy for patients. Mark ... is delivering the results today in an oral ...
(Date:10/8/2015)... Oct. 8, 2015  Following months of investigation, Ross ... the nation alleging that the anticoagulant Xarelto,s recommended dosage doesn,t ... Philadelphia on behalf of a ... stroke because the drug didn,t work as the manufacturer suggested. ... other suits shortly on behalf of clients from across the ...
Breaking Medicine Technology:
Cached News: